Pfizer stock (NYSE: PFE) lost about 5% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly ...
Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped ...
San Francisco — La voie semble désormais libre pour le rachat par Pfizer de la biotech américaine Metsera, spécialiste des ...
La voie semble désormais libre pour le rachat par Pfizer de la biotech américaine Metsera, spécialiste des traitements ...
BFM Business on MSN
Novo Nordisk jette l'éponge, Pfizer a le champ libre
Pfizer s'apprête à acquérir Metsera, spécialiste des traitements anti-obésité, après l'acceptation d'une offre relevée. Novo ...
With a market cap of $144.8 billion, New York-based Pfizer Inc. (PFE) is a global biopharmaceutical company that discovers, develops, and markets innovative medicines and vaccines across diverse ...
Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...
We recently published 11 Stocks Crushing Wall Street With Whopping Gains. Pfizer Inc. (NYSE:PFE) is one of the top performers on Tuesday. Pfizer Inc. extended its winning streak to a third straight ...
Pfizer Inc. (NYSE:PFE) is included among the 12 Best Dividend Paying Stocks to Buy Now. Pfizer Inc. (NYSE:PFE) ranks among the world’s top pharmaceutical companies, with vast resources to back its ...
In the latest close session, Pfizer (PFE) was up +1.16% at $24.51. The stock outpaced the S&P 500's daily gain of 0.53%. Elsewhere, the Dow saw an upswing of 0.52%, while the tech-heavy Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback